Physiomics gains first large pharma customer

RNS Number : 4031P

Physiomics PLC

01 October 2013

 



Physiomics plc

("Physiomics") or ("the Company")

Physiomics gains first large pharma customer for modelling cardiac toxicity risk

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has signed a contract with its first large pharma customer to supply cardiac toxicity risk modelling services.

The Initial contract runs for 12 months and involves a number of compounds which will be put through one of our cardiac toxicity models. The Directors hope that this will lead to a more extensive interaction in future as the benefits of this strategy become apparent.

Cardiac toxicity is a well-known risk factor in drug development.  Candidate drugs are routinely screened using laboratory-based tests, which are not always predictive, are costly and time consuming.  Physiomics has developed a suite of virtual cardiotox platforms which can be used to rapidly assess risk at a relatively early stage of development, for minimal cost per compound. These platforms were presented recently at the safety pharmacology society's annual meeting, as stated in our 16^th of September announcement.

More information about the service may be found at:

http://www.physiomics-plc.com/services/cardiac-toxicity-service/

Dr Mark Chadwick, CEO of Physiomics, commented:

"We are very pleased to have signed up our first large pharma customer for this important new model. Our cardiotox platform has generated significant interest particularly amongst large pharma companies and regulatory agencies."

Enquiries:

Physiomics plc                                                  

Dr Mark Chadwick, CEO

[phone]

WH Ireland Limited (broker/nomad)

Katy Mitchell

[phone]

About Physiomics plc

Physiomics (AIM:PYC) is a computational systems biology services company applying simulations of cell behaviour to drug development to reduce the high attrition rates of clinical trials. 80-90 per cent of all clinical drug candidates fail to reach the market and estimates show that an overall ten per cent improvement in success rates could reduce the cost of one drug's development by as much as $242 million, from the current estimate of around $800 million¹.

Physiomics develops computational systems biology models to predict and understand cancer drug efficacy from pre-clinical research to clinical development. Physiomics has created detailed mathematical models incorporating the most important molecular events taking place during the human cell cycle and apoptosis processes. The company's SystemCell® technology enables the simulation of populations of "virtual cells". The company has also developed a "Virtual Tumour" model to simulate the effect of anti-cancer drugs on tumour growth. The models are used to optimise compound design and to design drug schedules and combination therapies.

Physiomics, based in Oxford, UK, was founded in 2001, and floated on AIM in 2004. For further information, please visit www.physiomics-plc.com

SystemCell® is a registered trademark of Physiomics plc

¹Tufts Centre Impact Report 2002

 

END

 

 

NRAUGGGCUUPWGUG